Table 1. Bacillus anthracis toxin-directed agents available for or close to clinical use.

Agent designation	Description	Manufacturer	Stage of development
AIG [37]	pAb Inhibits PA binding domain	Emergent Biosolutions	Undergoing FDA review Included in SNS
Raxibacumab (Abthrax) [39]	Humanized mAb Inhibits PA binding domain	GlaxoSmithKline	FDA approved Included in SNS
ETI-204 (Anthium) [43]	Humanized mAb Inhibits PA binding domain	Elusys Therapeutics	Reportedly completed Phase I testing Fast-track and orphan drug status by the FDA
IQNPA [45]	Human mAb Inhibits PA binding domain and LF	IQ Corporation	Reportedly undergoing Phase I testing
AVP-21D9 [71,73-75]	Human mAb Interferes with oligomer formation	Avanir Pharmaceuticals	Reportedly completed Phase I testing Published data available
MDX 1303 (Valortim) [76-78]	Human mAb Interferes with oligomer formation	Emergent Biosolutions	Reportedly completed Phase I testing Fast-track and orphan drug status by the FDA

AIG: Anthrax Immune Globulin; AVA: anthrax vaccine adsorbed; FDA: Food and Drug Administration; LF: Lethal factor; PA: Protective antigen; pAb: Polyclonal antibody; SNS: Strategic National Stockpile.